Leerink analyst Geoffrey Porges believes shares of Regeneron Pharmaceuticals have 5%-7% upside on positive SOLO data. The analyst expects top-line results for Dupilumab Phase III SOLO 1 and 2 studies in moderate to severe atopic dermatitis by the end of Q1. To meet his expectations, dupilumab needs to show 25%-30% of patients achieving the investigator global assessment endpoint at 16 weeks and a mean percentage change in the EASI score of 45%-55%, or better. Anything below 20% on the primary endpoint, or 60% on the EASI score secondary endpoint, would likely be regarded as a disappointment, Porges tells investors in a research note. He has a positive view on the trial outcomes and maintains an Outperform rating on Regeneron with a $505 price target. The drugmaker closed yesterday at $365.47.